Citation Impact
Citing Papers
Advances in the diagnosis and treatment of Clostridium difficile infections
2018
Mucosal healing in inflammatory bowel diseases: a systematic review
2012 Standout
The gut microbiota and host health: a new clinical frontier
2015 Standout
Microbiota in health and diseases
2022 Standout
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Non-traditional Antibacterial Therapeutic Options and Challenges
2019
Are There Any Differences in the Efficacy and Safety of Different Formulations of Oral 5-ASA Used for Induction and Maintenance of Remission in Ulcerative Colitis? Evidence from Cochrane Reviews
2013
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
2013 Standout
A double‐blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis
2002
Ulcerative Colitis
2011 Standout
European evidence based consensus for endoscopy in inflammatory bowel disease
2013 Standout
Antibiotic resistance: a rundown of a global crisis
2018 Standout
Inflammatory bowel disease: clinical aspects and established and evolving therapies
2007 Standout
Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee
2004 Standout
The changing landscape of atherosclerosis
2021 StandoutNature
Antibiotic development — economic, regulatory and societal challenges
2019 Standout
Emerging Trends in “Smart Probiotics”: Functional Consideration for the Development of Novel Health and Industrial Applications
2017
The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study
2001 Standout
Biologic therapy of inflammatory bowel disease
2002
Ulcerative colitis
2012 Standout
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
2021 Standout
Crohn's disease
2016 Standout
Antioxidant therapy for treatment of inflammatory bowel disease: Does it work?
2015 Standout
Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease
2017
A Randomized, Placebo-Controlled, Phase II Study of Tetomilast in Active Ulcerative Colitis
2006
Disease Activity Assessment in IBD
2015
Medical therapy for ulcerative colitis 2004
2004
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management
2012
Ulcerative colitis
2016 Standout
Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee
2010
Biomarkers of Inflammation in Inflammatory Bowel Disease
2015
Hidradenitis suppurativa
2020 Standout
Ulcerative colitis
2020 Standout
Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases
2019 Standout
New targets for mucosal healing and therapy in inflammatory bowel diseases
2013
Current Evidence in Delivery and Therapeutic Uses of Fecal Microbiota Transplantation in Human Diseases—Clostridium difficile Disease and Beyond
2018
Opportunities for Treg cell therapy for the treatment of human disease
2023 StandoutNobel
CXCR3 ligands in disease and therapy
2014
Management of Crohn's Disease in Adults
2009 Standout
The pros, cons, and many unknowns of probiotics
2019 Standout
Curcumin Maintenance Therapy for Ulcerative Colitis: Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial
2006 Standout
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
2005 Standout
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis
2006
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
2016
Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis
2018
Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660—A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection
2018
Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission
2017
Once-Daily, High-Concentration MMX Mesalamine in Active Ulcerative Colitis
2006
European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis
2008
A Diet Low in Red and Processed Meat Does Not Reduce Rate of Crohn’s Disease Flares
2019 Standout
NOD2 Regulates CXCR3-Dependent CD8+ T Cell Accumulation in Intestinal Tissues with Acute Injury
2014
Quality indicators for colonoscopy
2014 Standout
Atherosclerotic Plaque Healing
2020
A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review
2019
A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis
2006 Standout
European evidence-based Consensus on the management of ulcerative colitis: Current management
2008
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis
2016
Inflammatory bowel disease biopsies: updated British Society of Gastroenterology reporting guidelines
2013
Nod2 Deficiency Augments Th17 Responses and Exacerbates Autoimmune Arthritis
2018 StandoutNobel
Works of Robert Hardi being referenced
Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study
2013
Safety and Durability of RBX2660 (Microbiota Suspension) for RecurrentClostridium difficileInfection: Results of the PUNCH CD Study
2015
Balsalazide Is Superior to Mesalamine in the Time to Improvement of Signs and Symptoms of Acute Mild-to-Moderate Ulcerative Colitis
2002
Extracorporeal photopheresis for the treatment of refractory Crohnʼs disease: Results of an open-label pilot study
2009
Mesalamine Dose Escalation Reduces Fecal Calprotectin in Patients With Quiescent Ulcerative Colitis
2014
Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute ulcerative colitis
2000
Human recombinant interleukin-10 is safe and well tolerated but does not induce remission in steroid dependent Crohn's disease
2001
862 A Randomized Controlled Trial of Mesalamine Dose Escalation for Ulcerative Colitis in Remission
2014
704 A Phase 1 Open-Label, Single-Dose, Dose-Escalation Study of Mdx-1100, a High-Affinity, Neutralizing, Fully Human Igg1κ Anti-CXCL10 (Ip10) Monoclonal Antibody, in Ulcerative Colitis
2008